The Food and Drug Administration (FDA) has directed the manufacturers of drugs approved for attention deficit hyperactivity disorder (ADHD) to add cautions of possible adverse cardiovascular and psychiatric adverse events to the literature for patients and caretakers.

The FDA advises that the manufacturers must now provide Patient Medication Guides outlining potential risks and precautions for the use of these various ADHD drugs. These guides are provided through the pharmacy when a prescription is filled

Several drugs used to treat attention deficit disorder, including Dexedrine and Ritalin, must include new warning information, the Food and Drug Administration said Monday. The FDA said the new warnings include possible risk of sudden death, serious heart problems, aggression, mania, psychotic behavior, stunted growth, seizures and vision problems.

Food and Drug Administration spokeswoman Susan Bro told Reuters she could not confirm whether the ADHD drugs Concerta and Strattera will also have to carry the warnings

Federal health advisers are considering putting stronger warning labels on drugs to treat attention deficit hyperactivity disorder or ADHD. Health officials say reports of psychosis or mania in children have been associated with the increasingly popular medications used to treat attention deficit hyperactivity disorder.

Reviews released in advance of a meeting Wednesday cover some 90 studies on the drugs Ritalin, Adderall, and Strattera, as well as reports from doctors, parents and others

Decision Resources, a leading research and advisory firm focusing on pharmaceutical and healthcare issues, finds there is significant commercial opportunity for pharmaceutical companies interested in entering the drug market to treat adult Attention-Deficit/Hyperactivity Disorder (ADHD).

The reason behind their announcement on Monday, recent studies have shown that the prevalence of adult ADHD in the United States tops 4 percent

Eli Lilly and Co. will add a "black-box warning" to its attention deficit medication Strattera, saying the drug may increase suicidal thoughts among younger patients.

The move comes after the U.S. Food and Drug Administration (FDA) issued a health advisory bsaed on clinical trials conducted on the drug